vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是COMSCORE, INC.的1.7倍（$156.4M vs $93.5M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs -1.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 3.8%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
BCRX vs SCOR — 直观对比
营收规模更大
BCRX
是对方的1.7倍
$93.5M
营收增速更快
BCRX
高出9.0%
-1.5%
两年增速更快
BCRX
近两年复合增速
3.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $93.5M |
| 净利润 | — | $3.0M |
| 毛利率 | — | 41.0% |
| 营业利润率 | 13.6% | 7.0% |
| 净利率 | — | 3.2% |
| 营收同比 | 7.5% | -1.5% |
| 净利润同比 | — | -3.7% |
| 每股收益（稀释后） | $0.00 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXSCOR
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $93.5M | ||
| Q3 25 | $159.4M | $88.9M | ||
| Q2 25 | $163.4M | $89.4M | ||
| Q1 25 | $145.5M | $85.7M | ||
| Q4 24 | $131.5M | $94.9M | ||
| Q3 24 | $117.1M | $88.5M | ||
| Q2 24 | $109.3M | $85.8M |
净利润BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $3.0M | ||
| Q3 25 | $12.9M | $453.0K | ||
| Q2 25 | $5.1M | $-9.5M | ||
| Q1 25 | $32.0K | $-4.0M | ||
| Q4 24 | $-26.8M | $3.1M | ||
| Q3 24 | $-14.0M | $-60.6M | ||
| Q2 24 | $-12.7M | $-1.7M |
毛利率BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 41.0% | ||
| Q3 25 | 98.6% | 40.6% | ||
| Q2 25 | 98.3% | 40.6% | ||
| Q1 25 | 96.9% | 39.6% | ||
| Q4 24 | 95.4% | 42.4% | ||
| Q3 24 | 97.3% | 41.2% | ||
| Q2 24 | 98.4% | 39.5% |
营业利润率BCRXSCOR
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 7.0% | ||
| Q3 25 | 18.6% | 1.9% | ||
| Q2 25 | 18.2% | -1.9% | ||
| Q1 25 | 14.6% | -2.4% | ||
| Q4 24 | -3.4% | 4.1% | ||
| Q3 24 | 6.6% | -67.4% | ||
| Q2 24 | 8.0% | -2.2% |
净利率BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 3.2% | ||
| Q3 25 | 8.1% | 0.5% | ||
| Q2 25 | 3.1% | -10.6% | ||
| Q1 25 | 0.0% | -4.7% | ||
| Q4 24 | -20.4% | 3.3% | ||
| Q3 24 | -12.0% | -68.5% | ||
| Q2 24 | -11.6% | -2.0% |
每股收益（稀释后）BCRXSCOR
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $9.50 | ||
| Q3 25 | $0.06 | $-0.86 | ||
| Q2 25 | $0.02 | $-2.73 | ||
| Q1 25 | $0.00 | $-1.66 | ||
| Q4 24 | $-0.13 | $-0.47 | ||
| Q3 24 | $-0.07 | $-12.79 | ||
| Q2 24 | $-0.06 | $-1.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $23.6M |
| 总债务越低越好 | — | $41.5M |
| 股东权益账面价值 | — | $111.4M |
| 总资产 | $465.1M | $407.7M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资BCRXSCOR
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $23.6M | ||
| Q3 25 | $212.9M | $26.7M | ||
| Q2 25 | $260.0M | $26.0M | ||
| Q1 25 | $295.1M | $31.0M | ||
| Q4 24 | $320.9M | $29.9M | ||
| Q3 24 | $96.8M | $20.0M | ||
| Q2 24 | $78.4M | $14.7M |
总债务BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $111.4M | ||
| Q3 25 | $-387.9M | $-26.3M | ||
| Q2 25 | $-421.6M | $-21.7M | ||
| Q1 25 | $-451.9M | $-13.5M | ||
| Q4 24 | $-475.9M | $-8.3M | ||
| Q3 24 | $-468.6M | $-2.7M | ||
| Q2 24 | $-475.6M | $45.8M |
总资产BCRXSCOR
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $407.7M | ||
| Q3 25 | $446.4M | $406.9M | ||
| Q2 25 | $457.2M | $415.9M | ||
| Q1 25 | $480.0M | $421.5M | ||
| Q4 24 | $490.4M | $430.2M | ||
| Q3 24 | $491.3M | $412.5M | ||
| Q2 24 | $472.4M | $474.1M |
负债/权益比BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $3.2M |
| 自由现金流经营现金流 - 资本支出 | — | $2.9M |
| 自由现金流率自由现金流/营收 | — | 3.1% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.07× |
| 过去12个月自由现金流最近4个季度 | — | $21.8M |
8季度趋势，按日历期对齐
经营现金流BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $3.2M | ||
| Q3 25 | $41.6M | $9.5M | ||
| Q2 25 | $41.3M | $932.0K | ||
| Q1 25 | $-27.5M | $9.1M | ||
| Q4 24 | $-5.2M | $-10.0M | ||
| Q3 24 | $8.2M | $12.5M | ||
| Q2 24 | $-1.4M | $8.7M |
自由现金流BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $2.9M | ||
| Q3 25 | $40.3M | $9.4M | ||
| Q2 25 | $41.1M | $787.0K | ||
| Q1 25 | $-27.7M | $8.7M | ||
| Q4 24 | $-5.9M | $-10.3M | ||
| Q3 24 | $8.2M | $12.4M | ||
| Q2 24 | $-1.5M | $8.5M |
自由现金流率BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 3.1% | ||
| Q3 25 | 25.3% | 10.5% | ||
| Q2 25 | 25.2% | 0.9% | ||
| Q1 25 | -19.0% | 10.1% | ||
| Q4 24 | -4.5% | -10.8% | ||
| Q3 24 | 7.0% | 14.0% | ||
| Q2 24 | -1.4% | 10.0% |
资本支出强度BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.3% | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.1% | 0.4% | ||
| Q4 24 | 0.5% | 0.2% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.2% |
现金转化率BCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 1.07× | ||
| Q3 25 | 3.23× | 20.96× | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
